- Hemostemix (HEM) has announced a non-brokered private placement for gross proceeds of up to $1,008,000
- The company will issue up to 7,200,000 units at a price of $0.14 per unit
- Proceeds from the offering will be used to pay current filing and regulatory fees, clinical trial costs and general working capital
- Hemostemix is an autologous stem cell therapy company
- Shares of Hemostemix Inc. (HEM) opened trading at C$0.145
Hemostemix (HEM) has announced a non-brokered private placement for gross proceeds of up to $1,008,000.
The company will issue up to 7,200,000 units at a price of $0.14 per unit. Each unit will consist of one common share and one share purchase warrant. Each warrant will entitle the holder to acquire one additional share at a price of $0.40 for a period of 24 months from the closing of the offering.
The warrants are subject to an acceleration clause.
Proceeds from the offering will be used to pay current filing and regulatory fees, clinical trial costs and general working capital.
All securities issued will be subject to a four-month hold period.
Hemostemix is an autologous stem cell therapy company. The company has developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
Shares of Hemostemix Inc. (HEM) opened trading at C$0.145.
